AstraZeneca's Lynparza Recommended by EU for Ovarian, Prostrate Cancer
21 September 2020 - 5:02PM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said on Monday that its Lynparza drug has been
recommended for approval in the European Union as first-line
maintenance treatment for HRD-positive advanced ovarian cancer, and
that it has also been recommended for marketing authorization by
the EU for patients with metastatic castration-resistant prostate
cancer.
The FTSE 100-listed drug maker also said that results from a
prespecified exploratory analysis of the positive ADAURA phase 3
trial showed its Tagrisso drug demonstrated a clinically-meaningful
improvement in central nervous system disease-free survival in
patients with early-stage epidermal growth factor receptor-mutated
non-small cell lung cancer after complete tumor resection. The
company said Tagrisso also reduced the risk of disease recurrence
in the brain by 82% in the adjuvant treatment of early-stage
epidermal growth factor receptor-mutated lung cancer.
The company said that advanced ovarian cancer patients treated
with Lynparza and drug bevacizumab lived without disease
progression for a median of 37.2 months versus 17.7 months for
bevacizumab alone.
The pharmaceutical company also said that for patients with
advanced ovarian cancer, the primary aim of first-line treatment is
to delay disease progression for as long as possible with the
intent to achieve long-term remission.
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 21, 2020 02:47 ET (06:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024